Zhao Y - Search Results

1

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.

Zhao Y, Griesel R, Omar Z, Simmons B, Hill A, van Zyl G, Keene C, Maartens G, Meintjes G. Zhao Y, et al. Clin Infect Dis. 2023 May 24;76(10):1832-1840. doi: 10.1093/cid/ciad023. Clin Infect Dis. 2023. PMID: 36645792 Free PMC article. Clinical Trial.

2

Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.

Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, Leslie J, Boulle A, Mudaly V, Kock Y, Meintjes G, Wasserman S. Zhao Y, et al. Clin Infect Dis. 2019 Apr 24;68(9):1522-1529. doi: 10.1093/cid/ciy727. Clin Infect Dis. 2019. PMID: 30165431 Free PMC article.

3

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.

Keene CM, Griesel R, Zhao Y, Gcwabe Z, Sayed K, Hill A, Cassidy T, Ngwenya O, Jackson A, van Zyl G, Schutz C, Goliath R, Flowers T, Goemaere E, Wiesner L, Simmons B, Maartens G, Meintjes G. Keene CM, et al. Among authors: zhao y. AIDS. 2021 Jul 15;35(9):1423-1432. doi: 10.1097/QAD.0000000000002936. AIDS. 2021. PMID: 33973876 Free PMC article.

4

Risk of Immune Reconstitution Inflammatory Syndrome With Integrase Inhibitors Versus Other Classes of Antiretrovirals: A Systematic Review and Meta-analysis of Randomized Trials.

Zhao Y, Hohlfeld A, Namale P, Meintjes G, Maartens G, Engel ME. Zhao Y, et al. J Acquir Immune Defic Syndr. 2022 Jun 1;90(2):232-239. doi: 10.1097/QAI.0000000000002937. J Acquir Immune Defic Syndr. 2022. PMID: 35175970 Free PMC article.

5

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial.

Zhao Y, Keene C, Griesel R, Sayed K, Gcwabe Z, Jackson A, Ngwenya O, Schutz C, Goliath R, Cassidy T, Goemaere E, Hill A, Maartens G, Meintjes G. Zhao Y, et al. Wellcome Open Res. 2021 Feb 17;6:33. doi: 10.12688/wellcomeopenres.16597.1. eCollection 2021. Wellcome Open Res. 2021. PMID: 36017341 Free PMC article.

6

Dolutegravir for second-line treatment: Programmatic implications of new evidence.

Zhao Y, Maartens G, Meintjes G. Zhao Y, et al. South Afr J HIV Med. 2022 Sep 5;23(1):1428. doi: 10.4102/sajhivmed.v23i1.1428. eCollection 2022. South Afr J HIV Med. 2022. PMID: 36299553 Free PMC article. No abstract available.

7

Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.

Keene CM, Cassidy T, Zhao Y, Griesel R, Jackson A, Sayed K, Omar Z, Hill A, Ngwenya O, Van Zyl G, Flowers T, Goemaere E, Maartens G, Meintjes G. Keene CM, et al. Among authors: zhao y. J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):422-429. doi: 10.1097/QAI.0000000000003157. J Acquir Immune Defic Syndr. 2023. PMID: 36706364 Free PMC article.

8

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene CM, Hill AM, Meintjes G, Maartens G. Griesel R, et al. Among authors: zhao y. Lancet HIV. 2023 Jul;10(7):e433-e441. doi: 10.1016/S2352-3018(23)00081-4. Epub 2023 May 22. Lancet HIV. 2023. PMID: 37230101 Free PMC article. Clinical Trial.

9

Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.

Griesel R, Banda CG, Zhao Y, Omar Z, Wiesner L, Meintjes G, Sinxadi P, Maartens G. Griesel R, et al. Among authors: zhao y. J Acquir Immune Defic Syndr. 2024 May 1;96(1):85-91. doi: 10.1097/QAI.0000000000003402. J Acquir Immune Defic Syndr. 2024. PMID: 38372621 Clinical Trial.

10

Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.

van Heerden JK, Meintjes G, Barr D, Zhao Y, Griesel R, Keene CM, Wiesner L, Galileya LT, Denti P, Maartens G. van Heerden JK, et al. Among authors: zhao y. J Acquir Immune Defic Syndr. 2024 Mar 1;95(3):260-267. doi: 10.1097/QAI.0000000000003341. J Acquir Immune Defic Syndr. 2024. PMID: 38408216 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

80,714 results

Search Page